Naratriptan Teva

Naratriptan, the active ingredient in Naratriptan Teva, is a Triptan (selective 5‑HT1B/1D receptor agonist) presented as an oral tablet. It is indicated for the acute treatment of migraine attacks in adult patients, providing relief from headache pain and associated symptoms such as nausea, photophobia, and phonophobia.

GNH USA supplies Naratriptan Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. All shipments are accompanied by full documentation for customs clearance.

Naratriptan is used in the acute management of migraine, a disorder involving cranial blood vessel dilation and trigeminal nerve activation. - Migraine attack: provides rapid relief of headache pain and associated symptoms. - Migraine with aura: reduces severity of aura‑related discomfort when taken early. - Acute episodic migraine: helps abort attacks in patients with episodic migraine patterns.

Naratriptan may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: mild stomach upset or urge to vomit. - Dry mouth: reduced salivation leading to a parched feeling. - Fatigue: feeling unusually tired or weak. - Tingling: transient paresthesia in extremities.

Serious or Rare Side Effects: - Chest discomfort: pressure or pain that may suggest cardiac involvement. - Serotonin syndrome: agitation, hyperthermia, and neuromuscular abnormalities when combined with other serotonergic agents. - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Severe hypertension: sudden increase in blood pressure. - Ischemic events: rare cases of stroke or myocardial infarction.

When prescribing Naratriptan, clinicians should consider several precautionary measures to ensure safe use. - Cardiovascular assessment: avoid use in patients with uncontrolled hypertension or coronary artery disease. - Medication history: review for concurrent serotonergic drugs to reduce risk of serotonin syndrome. - Age considerations: use with caution in elderly patients due to increased sensitivity to side effects. - Pregnancy and lactation: assess risk–benefit, as safety data are limited. - Driving and machinery: advise patients that dizziness may impair ability to operate vehicles. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture.

Naratriptan can interact with other medicines, altering its efficacy or increasing adverse effect risk.

Major Interactions (Avoid): - MAO inhibitors: concurrent use may precipitate severe hypertension. - Ergot alkaloids: combined vasoconstriction can lead to coronary spasm. - SSRIs/SNRIs: increased risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance antihypertensive effect, requiring blood pressure monitoring. - CYP1A2 inhibitors (e.g., fluvoxamine): can raise naratriptan plasma levels. - Antihypertensive agents: monitor for additive blood pressure lowering.